首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   78088篇
  免费   7468篇
  国内免费   4845篇
耳鼻咽喉   581篇
儿科学   1024篇
妇产科学   1241篇
基础医学   9298篇
口腔科学   1557篇
临床医学   9249篇
内科学   11897篇
皮肤病学   822篇
神经病学   4313篇
特种医学   2811篇
外国民族医学   32篇
外科学   7700篇
综合类   12880篇
一般理论   12篇
预防医学   5271篇
眼科学   2088篇
药学   8568篇
  62篇
中国医学   4392篇
肿瘤学   6603篇
  2024年   69篇
  2023年   1194篇
  2022年   1942篇
  2021年   3288篇
  2020年   3207篇
  2019年   3557篇
  2018年   2322篇
  2017年   2442篇
  2016年   2043篇
  2015年   3387篇
  2014年   4280篇
  2013年   4006篇
  2012年   6076篇
  2011年   6396篇
  2010年   4166篇
  2009年   3286篇
  2008年   4446篇
  2007年   4281篇
  2006年   3875篇
  2005年   3809篇
  2004年   2751篇
  2003年   2493篇
  2002年   2223篇
  2001年   1819篇
  2000年   1894篇
  1999年   1980篇
  1998年   1246篇
  1997年   1230篇
  1996年   962篇
  1995年   949篇
  1994年   780篇
  1993年   487篇
  1992年   562篇
  1991年   511篇
  1990年   430篇
  1989年   387篇
  1988年   301篇
  1987年   299篇
  1986年   233篇
  1985年   184篇
  1984年   119篇
  1983年   82篇
  1982年   58篇
  1981年   46篇
  1980年   33篇
  1979年   44篇
  1978年   18篇
  1974年   17篇
  1972年   16篇
  1966年   18篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC.  相似文献   
2.
3.
Formal multidisciplinary team (MDT) discussions in clinical practice require time and space but have unclear survival benefits for advanced gastrointestinal cancer patients. Our study aimed to investigate the long-term survival of patients with advanced gastrointestinal cancer after MDT decision. From June 2017 to June 2019, continuous MDT discussions on advanced gastrointestinal cancer were conducted in 13 medical centers in China. MDT decisions and actual treatment received by patients were prospectively recorded. The primary endpoint was the difference in overall survival (OS) between patients in the MDT decision implementation and nonimplementation groups. The secondary endpoints included the implementation rate of MDT decisions and subgroup survival analysis. A total of 461 MDT decisions of 455 patients were included in our study. The implementation rate of MDT decisions was 85.7%. Previous treatment had an impact on MDT decision-making. The OS was 24.0 months and 17.0 months in the implementation and nonimplementation groups, respectively. The implementation of MDT decisions significantly reduced the risk of death in multivariate analyses (hazard ratio = 0.518; 95% confidence interval: 0.304-0.884, P = .016). Subgroup analysis showed a significant difference in survival of patients with colorectal cancer, but not in survival of patients with gastric cancer. The rate of secondary MDT discussion was only 5.6% among patients who the MDT decisions were discontinued due to changes in their condition. MDT discussion can prolong the OS of patients with advanced gastrointestinal cancer, especially those with colorectal cancer. Timely scheduling of the subsequent MDT discussion is necessary when the disease condition changes.  相似文献   
4.
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes.  相似文献   
5.
目的探讨妊娠合并肺动脉高压患者剖宫产围产期并发症的危险因素。方法该研究为病例对照研究。回顾性纳入山东大学齐鲁医院、山东第一医科大学附属省立医院、山东省千佛山医院和青岛大学附属医院2010年5月至2020年5月妊娠合并肺动脉高压患者。根据是否发生剖宫产围产期并发症分为并发症组和对照组。收集患者的一般临床资料和辅助检查结果, 记录患者发生围产期并发症的情况。围产期并发症包括心功能恶化、新发心律失常、心脏骤停、术后42 d内全因死亡、产后出血及血栓事件。采用多因素logistic回归模型分析妊娠合并肺动脉高压患者剖宫产围产期并发症的危险因素。结果研究纳入患者167例, 年龄28(24, 32)岁, 其中并发症组47例, 对照组120例。两组患者年龄, 孕周, 初产妇、存在心内分流及接受靶向药物治疗者比例, 左、右心室舒张末期内径差异均无统计学意义(P均>0.05)。与对照组比较, 并发症组患者特发性肺动脉高压者比例较高(P=0.001)、接受全身麻醉的比例较高(P=0.001)、超声心动图估测的肺动脉收缩压较高(P<0.001)、术前世界卫生组织(WHO)功能Ⅲ/Ⅳ级者比例较高(...  相似文献   
6.
目的观察老年冠心病患者移动健康管理模式的构建, 并进行实证研究。方法选取2019年1月至2021年1月于河南省人民医院接受治疗的86例老年冠心病患者, 随机数字表法分为两组, 每组各43例, 对照组实施常规干预, 观察组在常规干预基础上应用移动健康管理模式进行干预, 两组均干预3个月, 评估患者心绞痛情况、再入院危险因素控制评价指标达标情况[低密度脂蛋白胆固醇(LDL-C)、静息心率、收缩压、舒张压];于干预前、干预3个月, 评估患者自护能力。结果观察组心绞痛发作次数少于对照组[(0.53±0.18)次/周和(0.64±0.15)次/周, t=3.079, P=0.003], 持续时间短于对照组[(2.72±0.40)min和(3.06±0.55)min, t=3.278, P=0.002];观察组再入院危险因素LDL-C(90.7%比72.1%, χ2=4.914, P=0.027)、静息心率(95.4%比81.4%, χ2=4.074, P=0.044)、收缩压(86.1%比60.5%, χ2=7.182, P=0.007)、舒张压达标率(88.4%比67.4%, χ2=5.472...  相似文献   
7.
Folayan  Morenike Oluwatoyin  Ibigbami  Olanrewaju  Brown  Brandon  El Tantawi  Maha  Uzochukwu  Benjamin  Ezechi  Oliver C.  Aly  Nourhan M.  Abeldaño  Giuliana Florencia  Ara  Eshrat  Ayanore  Martin Amogre  Ayoola  Oluwagbemiga O.  Osamika  Bamidele Emmanuel  Ellakany  Passent  Gaffar  Balgis  Idigbe  Ifeoma  Ishabiyi  Anthonia Omotola  Jafer  Mohammed  Khan  Abeedha Tu-Allah  Khalid  Zumama  Lawal  Folake Barakat  Lusher  Joanne  Nzimande  Ntombifuthi P.  Popoola  Bamidele Olubukola  Quadri  Mir Faeq Ali  Rashwan  Maher  Roque  Mark  Shamala  Anas  Al-Tammemi  Ala’a B.  Yousaf  Muhammad Abrar  Abeldaño Zuñiga  Roberto Ariel  Okeibunor  Joseph Chukwudi  Nguyen  Annie Lu 《AIDS and behavior》2022,26(3):739-751
AIDS and Behavior - The aim of the study was to assess if there were significant differences in the adoption of COVID-19 risk preventive behaviors and experience of food insecurity by people living...  相似文献   
8.
AIDS and Behavior - Pre-Exposure Prophylaxis (PrEP) health campaigns invite women to talk with their provider, partner, and peers about PrEP, though they do not offer specific guidance about who...  相似文献   
9.
王露 《当代医学》2022,28(3):30-32
目的探讨霉菌性外耳道炎患者接受耳内镜下外耳道冲洗联合酮康唑纱条治疗的临床效果。方法选取2018年2月至2019年3月本院收治的89例霉菌性外耳道炎患者,分为对照组(n=44)与观察组(n=45)。两组均进行耳内镜下外耳道冲洗,对照组在此基础上联合复发水杨酸滴耳治疗,观察组在外耳道冲洗基础上加用酮康唑纱条治疗。比较两组临床疗效和复发率。结果观察组治疗总有效率(93.33%)高于对照组(72.73%),差异有统计学意义(P<0.05);随访8个月,观察组复发率(8.89%)低于对照组(25.00%),差异有统计学意义(P<0.05)。结论耳内镜下外耳道冲洗联合酮康唑纱条治疗霉菌性外耳道炎患者有利于提高治疗有效率,降低疾病复发率。  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号